Registration - In-house Corporation

Indivior Canada Ltd. / Manon Lafontaine, General Manager

Registration Information

In-house Corporation name: Indivior Canada Ltd.
Previous in-house corporation names
Responsible Officer Name: Manon Lafontaine, General Manager
Responsible Officer Change History
Initial registration start date: 2011-05-24
Registration status: Active
Registration Number: 954995-280204

Associated Communications

Total Number of Communication Reports: 28

Monthly communication reports in the last 6 months: 0

Version 2 of 21 (2011-05-25 to 2012-01-01)

Registration versions:

Version 2 of 21 (2011-05-25 to 2012-01-01)

Lobbying Information

Subject Matters

Aboriginal Affairs
Budget
Consumer Issues
Health
Industry
Intellectual Property
International Trade
Research and Development
Science and Technology
Taxation and Finance

Subject Matter Details

Legislative Proposal, Bill or Resolution

The upcoming Food and Drugs Act Modernization legislative proposal (Act and Regulations) as it relates to improving the efficiency of the drug review and approval process.

Legislative Proposal, Bill or Resolution, Regulation

Food and Drugs Act & Regulations with respect to Drug Export Restrictions and international trade.
The Food and Drugs Act and Regulations with respect to their impact on addiction treatments.

Policies or Program

A national pharmacare strategy with respect to the need for full coverage/reimbursement of opioid dependence treatments and addiction treatments.
Common Drug Review with respect to reimbursement decisions and the approval process.
Coverage of opioid dependence treatments and addiction treatments with respect to Canadian Forces returning to Canada from active duty overseas.
Government of Canada Drug Plans, with respect to the reimbursement of therapeutic products relevant beneficiaries.
Non-Insured Health Benefits under Health Canada with regards to reimbursement criteria of opioid dependence & addiction treatments for First Nations, Inuit and Metis in Canada.
The National Anti-Drug Strategy with respect to public relations and awareness programs relating to addiction and opioid dependence.
The federal Science & Technology Strategy and/or any federal Government policy or program initiatives to support Research and Development in Canada, and advocate for the development of a pharmaceutical sectoral strategy in support of more research & development in Canada

Regulation

Patented Medicine Prices Review Board (PMPRB) Regulations as it relates to reporting requirements and pricing guidelines.
Patented Medicines Regulations (Notice of Compliance) with respect to regulating intellectual property for therapeutic products

Communication Techniques

Written communication
Oral communication
Participation in Industry Associations and delegations

Government Institutions

Aboriginal Affairs and Northern Development Canada
Canadian Institutes of Health Research (CIHR)
Correctional Service of Canada (CSC)
Finance Canada (FIN)
Foreign Affairs and International Trade Canada (DFAITC)
Health Canada (HC)
House of Commons
Industry Canada
Justice Canada (JC)
National Defence (DND)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Safety Canada (PS)
Royal Canadian Mounted Police (RCMP)
Senate of Canada
Veterans Affairs Canada (VAC)

In-house Corporation Details

Description of activities

Reckitt Benckiser Pharmaceuticals Inc. is committed to optimizing standards of patient care and minimizing risks of diversion and abuse through programs of education and intervention that we believe represent a benchmark for the pharmaceutical industry in the therapeutic area of addiction treatment.

Responsible officer name and position during the period of this registration

Gary Phillips, President & CEO (North America)

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
10710 Midlothian Turnpike
Richmond, VA 23235
United States of America

Telephone number: 804-379-1090
Fax number: 804-379-1215

Parent Company Information

Reckitt Benckiser Group / Groupe Reckitt Benckiser
- Suite 103
  105 Bath Road
  Slough, Berkshire SL13UH
  United Kingdom

Subsidiary Beneficiary Information

RB Pharmaceuticals Ltd. / RB Pharmaceuticals Ltd
- 103 - 105 Bath Road
  Slough, Berkshire SL13UH
  United Kingdom

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Tina Cantrill, Business Unit Director (Canada) | No public offices held
Rolley Johnson, Vice President, Treatment & Health Policy | No public offices held
Gary Phillips, President & CEO (North America) | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Cameron Bishop, Manager, Treatment, Health Policy & Government Affairs | Public offices held

Indivior Canada Ltd.

The following names have been used on or after July 2, 2008

Name	From	To
Indivior Canada Ltd.	2023-04-09	current
Indivior Canada Ltd./Indivior (Canada) Ltd.	2015-07-01	2017-07-16
RBP Canada Ltd., a subsidiary of Indivior PLC	2015-01-01	2015-07-01
Reckitt Benckiser Pharmaceuticals Inc/Reckitt Benckiser Pharmaceuticals Inc.	2011-05-24	2015-01-01

The following names have been used before July 2, 2008

Reckitt Benckiser Pharmaceuticals Inc/Reckitt Benckiser Pharmaceuticals Inc.

Indivior Canada Ltd.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Manon Lafontaine	2023-04-09	Current
Richard Simkin	2012-01-01	2017-07-16
Gary Phillips	2011-05-24	2012-01-01

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Press Secretary Health Canada, Office of the Minister of Public Health	January 2005 to February 2006	Not a designated office

Date Modified:: 2026-03-23

Search and menus

Language selection

Registration - In-house Corporation

Indivior Canada Ltd. / Manon Lafontaine, General Manager

Registration Information

Associated Communications

Version 2 of 21 (2011-05-25 to 2012-01-01)

Version 2 of 21 (2011-05-25 to 2012-01-01)

Subject Matters

Subject Matter Details

Legislative Proposal, Bill or Resolution

Legislative Proposal, Bill or Resolution, Regulation

Policies or Program

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties